Merck KGaA just made a quiet digital-health move. Could hybrid drugs be pharma’s next big reset?
Digital therapeutics struggled alone. Remepy and Merck KGaA are testing whether software works better when built into the drug itself.
Digital therapeutics struggled alone. Remepy and Merck KGaA are testing whether software works better when built into the drug itself.